• Premaitha secures four further laboratories in Europe

    Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European customer base, with four new laboratories added.

  • Lilly strengthens its oncology department with a new name

    Eli Lilly said on Monday that Kimberly Blackwell, M.D., one of the USA’s leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018. 

  • FDA will review Eli Lilly’s Galcanezumab for the prevention of migraine in adults

    Eli Lilly said on Monday that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. Galcanezumab has been submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe.

  • Juno, Calgene announce more potential of CAR T therapy

    Juno Therapeutics, a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation have additional data from the TRANSCEND study of JCAR017 in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (NHL).

  • prophylactic dosing with Alprolix provides safe and effective protection in people with severe haemophilia B

    SOBI and Bioverativ on Monday announced the results of a new post-hoc longitudinal analysis demonstrating that individualised dosing with extended half-life therapy, Alprolix, every 14 or more days may be a potential option for people with severe haemophilia B who seek the benefits of protection from a prophylactic therapy with

  • Tresiba reduces hypoglycaemia regardless of blood sugar level

    People with either type 1 or type 2 diabetes treated with Tresiba had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets, said Novo Nordisk.

  • ProcureCon Pharma 2018: event for senior pharma procurement professionals

    We are very proud to be partnering with the ProcureCon Pharma 2018, the only event in Europe for senior pharma procurement professionals and their teams.  Taking place on 13-15 March in Zurich, Switzerland, ProcureCon Pharma offers over 3 days and 40 interactive sessions that will help you make better outsourcing

  • GSK’s Shingrix able to prevent shingles in autologous haematopoietic stem cell transplant patients GSK

    GlaxoSmithKline said on Wednesday that new data from a Phase III clinical study supports the safety and efficacy of Shingrix ((Zoster Vaccine Recombinant, Adjuvanted) in preventing shingles (herpes zoster) when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant (auHSCT). Shingrix is a non-live, recombinant

  • ADC Bio signs construction agreement with sector specialists WHP

    ADC Biotechnology (ADC Bio) – a specialist ADC contract services company with proprietary conjugation technology designed to overcome process and aggregation challenges during the development of new antibody drug conjugates (ADCs) – announces the signing of a partnership agreement with multi-disciplined engineering specialists, WHP. 

  • Plasticell and Anthony Nolan to partner in clinical trials of ex vivo expanded cord blood stem cells

    Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex vivo expanded cord-blood derived hematopoietic stem cell product.